{"entity":{"id":"joseph-connors","kind":"person","name":"Joseph M. Connors","aka":[],"tldr":"Led ECHELON-1, which replaced bleomycin with brentuximab vedotin in first-line advanced Hodgkin lymphoma.","summary":"Joseph Connors was principal investigator of ECHELON-1, the trial showing brentuximab vedotin plus AVD improves progression-free and later overall survival compared with ABVD in advanced Hodgkin lymphoma, the first change to first-line therapy in decades. He built the BC Cancer lymphoid cancer database and population-based treatment guidelines that document real-world outcomes across all lymphomas.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Connors%20JM%5BAuthor%5D%20Hodgkin%20brentuximab"}],"tags":["hodgkin","adc","canada"],"related":[],"cancers":["hodgkin-lymphoma"],"sections":[],"technologies":["adc"],"targets":[],"drugs":["brentuximab-vedotin"],"companies":[],"institutions":["bc-cancer"],"pathways":[],"terms":[],"trials":["echelon-1"],"people":[],"bottlenecks":[],"keyPapers":["paper-echelon-1-brentuximab-avd-nejm-2018"],"journals":[],"dependsOn":[],"notes":[],"role":"Clinical Professor Emeritus, BC Cancer Centre for Lymphoid Cancer, University of British Columbia","institutionId":"bc-cancer","specialisms":["Hodgkin lymphoma","Population-based lymphoma care","Antibody-drug conjugates","Treatment guidelines"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Connors%20JM%5BAuthor%5D%20Hodgkin%20brentuximab"}],"papers":[{"title":"Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin's lymphoma (ECHELON-1)","journal":"NEJM","year":2018,"doi":"10.1056/NEJMoa1708984"},{"title":"Overall survival with brentuximab vedotin in stage III or IV Hodgkin's lymphoma","journal":"NEJM","year":2022,"doi":"10.1056/NEJMoa2206125"}]},"route":"/people/joseph-connors/","neighbours":{"cancer":[{"id":"hodgkin-lymphoma","kind":"cancer","name":"Hodgkin lymphoma","route":"/cancers/hodgkin-lymphoma/"}],"technology":[{"id":"adc","kind":"technology","name":"Antibody-drug conjugate (ADC)","route":"/technologies/adc/"}],"drug":[{"id":"brentuximab-vedotin","kind":"drug","name":"Brentuximab vedotin","route":"/drugs/brentuximab-vedotin/"}],"institution":[{"id":"bc-cancer","kind":"institution","name":"BC Cancer","route":"/institutions/bc-cancer/"}],"trial":[{"id":"echelon-1","kind":"trial","name":"ECHELON-1","route":"/trials/echelon-1/"}],"paper":[{"id":"paper-echelon-1-brentuximab-avd-nejm-2018","kind":"paper","name":"ECHELON-1: brentuximab vedotin replacing bleomycin in first-line chemotherapy for advanced Hodgkin lymphoma","route":"/key-papers/paper-echelon-1-brentuximab-avd-nejm-2018/"}]}}